iRadimed (IRMD) Set to Announce Quarterly Earnings on Friday

iRadimed (NASDAQ:IRMD) is expected to post its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect iRadimed to post earnings of $0.55 per share and revenue of $23.47 million for the quarter. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, October 30, 2026 at 11:00 AM ET.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.02. The company had revenue of $20.47 million during the quarter, compared to the consensus estimate of $20.35 million.

iRadimed Price Performance

Shares of IRMD opened at $83.95 on Wednesday. iRadimed has a 1 year low of $75.75 and a 1 year high of $107.90. The stock has a 50 day simple moving average of $85.96 and a 200-day simple moving average of $92.94.

iRadimed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 28th. Investors of record on Friday, August 14th were paid a $0.20 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.80 annualized dividend and a yield of 1.0%.

Wall Street Analyst Weigh In

IRMD has been the topic of a number of analyst reports. Weiss Ratings upgraded iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 16th. Wall Street Zen cut iRadimed from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Needham & Company LLC initiated coverage on iRadimed in a report on Tuesday, September 22nd. They set a “hold” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $120.00.

Insiders Place Their Bets

In other news, Director Monty K. Allen sold 1,419 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total transaction of $122,615.79. Following the transaction, the director directly owned 19,581 shares in the company, valued at approximately $1,691,994.21. This represents a 6.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 34.60% of the company’s stock.

About iRadimed

iRadimed Corporation (NASDAQ: IRMD) develops, manufactures and sells medical devices designed for use during magnetic resonance imaging (MRI) procedures. The company focuses on solutions that allow clinicians to deliver intravenous medications and monitor patients safely while they are in or near an MRI scanner.

Its principal products include the MRidium MRI-compatible infusion pump systems, which are designed to administer intravenous fluids and medications without interfering with MRI operations.